Kislaya, IrinaMachado, AusendaMagalhães, SarahRodrigues, Ana PaulaFranco, RafaelLeite, Pedro PintoDias, Carlos MatiasNunes, Baltazar2022-12-132022-12-132022-09-151025-496XPURE: 48293905PURE UUID: 69712c78-816e-4691-bcd0-2d8e19482d02Scopus: 85137882956PubMed: 36111555PubMedCentral: PMC9479470WOS: 000869739500003http://hdl.handle.net/10362/146191Funding Information: The authors are grateful to Marta Barreto and Verónica Gómez from the Department of Epidemiology of Instituto Nacional de Saúde Doutor Ricardo Jorge and Camila Cruz and João Lima from Shared Services of the Health Ministry for their contributions for this work. Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in≥80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.146052engEpidemiologyPublic Health, Environmental and Occupational HealthVirologySDG 3 - Good Health and Well-beingjournal article10.2807/1560-7917.ES.2022.27.37.2200697https://www.scopus.com/pages/publications/85137882956